Is it possible to identify original compounds that are able to enhance sperm motility from the venom of the scorpion Scorpio maurus palmatus?
Introduction
Sperm motility is a key parameter for fertilization. Mammalian fertilization occurs deep within the female tract, close to the oocyte release point and sperm, which is released in the vagina, must reach the meeting point by swimming through the female tract. Moreover, motility is also required for sperm to cross the protective layers surrounding the oocytes. Finally, sperm flagellum beating is also essential for gamete fusion (Ravaux et al., 2016) . The motility of sperm is thus crucial for the sperm to deliver its DNA content into the oocyte. As a consequence, any disturbance in sperm motility has a strong impact on fertilization and leads to subfertility or infertility. It was clearly shown that the percentage of conception depends on the number of motile sperm (Publicover and Barratt, 2011) and for these reasons, sperm motility is systematically assessed in a context of couple infertility. Sperm exhibiting absent or low motility, a condition known as asthenozoospermia, is an important cause of couple infertility and accounts for~20% of observed defects (Thonneau et al., 1991; Curi et al., 2003) .
Despite the development of ICSI, which even allows the treatment of patients presenting with complete sperm immobility (Wambergue et al., 2016) , sperm motility remains an important variable in ART. The discovery of a drug that could potently increase sperm motility would be first essential in the domain of cryopreservation because sperm cryopreservation is an important component of ART. Indeed, extreme low temperature treatment decreases the motility of frozenthawed sperm and thus hampers their ability to successfully fertilize the oocytes in artificial insemination (AI) as well as in IVF. Such a drug, with an ability to improve the motility of frozen-thawed sperm, would encourage practitioners to use IVF, which partially preserves the sperm selection that operates during natural fertilization instead of using routine ICSI, which may be associated with a higher risk of birth defects (Davies et al., 2012) . Secondly, such a compound would also be beneficial for azoospermic patients requiring testicular sperm extraction. Density gradient selection of motile sperm is often not useable because the number of sperm is very low, in particular in cases of non-obstructive azoospermia. Motile sperm can be more easily detected and recovery is greatly improved when sperm motility is enhanced and, furthermore, the selection of motile sperm ensures the selection of mature and likely viable spermatozoa. Enhancing sperm motility thus represents a key parameter to improve the extraction of mature sperm from testis biopsies. Sperm motility was also shown to be positively associated with the quality of the sperm nucleus (Nosrati et al., 2014) thus showing an added benefit to the selection of the most motile sperm. Moreover, such a drug would also be interesting for livestock, where AI with frozen-thawed sperm is heavily used, forcing the AI centers to increase sperm concentration in straws to circumvent the decreased motility of frozen-thawed sperm, reducing the overall success of the method.
For these reasons, significant efforts were made to identify pharmacological drugs able to improve sperm motility (Hammitt et al., 1989; Lanzafame et al., 1994) . Phosphorylation of sperm proteins, such as A-kinase anchoring proteins or glycogen synthase kinase-3 A, is a key control step inducing sperm motility (Somanath et al., 2004; Luconi et al., 2005) . A cascade of different kinases ending with protein kinase A (PKA) controls these phosphorylations (Luconi et al., 2004) . Because PKA is stimulated by increased concentrations of cyclic AMP, both inhibition of phosphodiesterase, which hydrolyzes cyclic AMP, and stimulation of cyclic-AMP production improve sperm motility. It was shown that stimulation of cyclic-AMP production by 2-deoxyadenosine, an analog of adenosine, increased the percentage of motile sperm and was also potent in improving the motility of frozenthawed human sperm (Aitken et al., 1986) . Another compound, kallikrein, which improves cyclic-AMP production through increased fructose transport across the plasma membrane, was shown to stimulate sperm motility (Schill, 1975) . The inhibitors of phosphodiesterase, for example xanthine derivatives such as pentoxifylline or caffeine, were successfully used to improve sperm motility (De et al., 1978) and to prepare testicular sperm (Tasdemir et al., 1998; Kovacic et al., 2006) . However, some concerns arose concerning the use of this family of drugs, such as low specificity (Tournaye et al., 1994) and activation of acrosome reaction, leading to a progressive disinterest in this compound (Terriou et al., 2015) . In order to find an alternative to xanthine derivatives, the screening of drugs able to more specifically inhibit sperm phosphodiesterases was performed recently and several compounds were identified including papaverine (Tardif et al., 2014) . Phosphoinositide (PI)-3 kinase, another kinase of the cascade ending with the PKA was also targeted. Because it has been shown that phosphorylation of PKA by PI-3 kinase inhibits sperm motility, inhibitors of PI-3 kinase, such as LY294002, were therefore tested and shown to be potent stimulators of sperm motility in human (Luconi et al., 2001) . It is worth noting that most of the studies performed on molecules able to improve sperm motility focused on the pathway controlling the activity of PKA. Only a few other compounds showing positive effects on sperm motility and involving other pathways, such as relexin or platelet activating factor, were characterized (Essig et al., 1982; Roudebush, 2001) . However, contradictory reports showed notable differences in their potency (Lanzafame et al., 1994) .
The aim of this work was to discover new bioactive natural compounds able to enhance sperm motility and unrelated to previous potent molecules in order to expand the range of molecules stimulating sperm motility. Moreover, these original compounds may highlight new molecular mechanisms controlling sperm motility and thus improve our limited knowledge of sperm motility.
To discover new pharmaceutical entities, large scientific programs have been launched all over the world to identify new drugs based on biotechnology and known as 'biologics'. The attractiveness of 'biologics' as novel drugs is attested by the success in bringing to market therapeutic peptides, proteins and antibodies, including over 140 peptides under clinical development and >50 therapeutic peptides on the market for >60 pathologies (Fosgerau and Hoffmann, 2015) . The potential of therapeutic proteins stems from their high selectivity (<0.1 nM), often at the receptor subtype level, which is a clinically important feature that limits their side effects. Among biologics, we will focus on the subset that are peptide-based drugs and in particular disulfide-rich peptides (DRPs). These peptides are conformationally constrained, which provides them with an exceptional in vivo stability. Since 2000, seven DRPs have been approved by the US Food and Drugs Administration, and several dozens of others are currently under preclinical or clinical evaluation (Gongora-Benitez et al., 2014) . Interestingly, venoms represent a remarkable source of DRPs with still unforeseen pharmacological profiles and thus represent an underexploited reservoir of pharmacological compounds (Vetter et al., 2011) . Because of the great potential of venom extracts, we performed the first sperm bioassay-driven analysis of venom extracts and demonstrated that animal venoms contain numerous compounds able to modulate sperm physiology (Escoffier et al., 2010 (Escoffier et al., , 2011 . In particular, we characterized several compounds able to inhibit sperm motility. During screening, several fractions of venoms were shown to improve mouse sperm motility. Here we showed that a fraction of the venom from the scorpion Scorpio maurus palmatus stimulates the motility of sperm from different mammalian species (human, non-human primates (NHP), bovine and mouse). Proteomic analysis enabled us to identify a peptide of 73 amino acids that we named spermaurin, which increased the motility of fresh and frozen-thawed ejaculated sperm in different mammalian species. Interestingly, spermaurin is also a potent drug to stimulate testicular sperm motility. Finally, we showed that spermaurin improves mouse IVF outcome.
Materials and Methods

Biological samples
Human sperm
Human sperm were obtained from patients consulting for diagnosis or undergoing ART at the fertility center of Grenoble University Hospital (Grenoble, France). The samples were then cryopreserved and stored in the Centre de Ressources Biologiques (CRB) Germetheque (certification under ISO-9001 and NF-S 96-900) following a standardized procedure. Consent for CRB storage was approved by the CPP Sud-Ouest of Toulouse, France (coordinator of the multi-site CRB Germetheque). The storage and cession authorization number for the CRB Germetheque is AC2009-886. The scientific and ethical board of the CRB Germetheque approved the cession of the semen samples for this study. The total number of human samples used in this study is 56.
Ejaculate was liquefied at 37°C for 30 min and sperm were washed twice in Sperm Preparation Medium (Origio, Målov, Denmark) by centrifugation at 500g for 5 min at room temperature. Concentration is then adjusted for computer-assisted sperm analysis (CASA) (~8 million/ml). Sperm were also frozen with SpermFreeze (Fertipro NV, Beernem, Belgium) for further analysis as frozen sperm. All patients consulted for couple infertility and we only used sperm with normal morphology parameters according to the World Health Organization 2010 guidelines (World Health Organization, 2010) .
All the patients signed an informed consent for use of part of their sample in research programs. Approval for the study was given by the Germetheque ethical board.
NHP sperm
Testes were collected from Mauritian cynomolgus monkeys (Macaca fascicularis), 4-6 years old, euthanized in the framework of another studies at MIRCen (CEA/INSERM UMR1169, Fontenay-aux-Roses, France; agreement number: 92-032-02). These animals had not received any treatment that could have affected spermatogenesis. Testis, with epididymis attached and kept at 4°C, were delivered and processed within 24 h after NHP death. Testicular sperm were collected from a biopsy, and seminiferous tubules dispersed with needles. Testicular sperm were selected by a swimup procedure (30 min, 37°C) and the upper fractions were washed twice in DMEM high glucose media (by centrifugation at 500g, 5 min). The total number of NHP samples used in this study is 3.
Bovine sperm
Testes were collected at the slaughter house and sperm extracted <3 h after bull death. Epididymal sperm were collected from the distal part of the caudae epididymis in non-capacitating medium sp-TALP (in mM: NaCl 114; KCl 3.2; NaH 2 PO 4 0.3; Na-Lactate 10; MgCl 2 0.5; HEPES 10; NaHCO 3 25; Na Pyruvate 1; 50 µg/ml Gentamicine; pH 7.4). Epididymal sperm were washed twice in sp-TALP. Frozen bovine sperm were obtained from IMV Technologies (L'Aigle-France) and conserved as straws in liquid nitrogen.
Mouse sperm
All protocols have been reviewed and approved by the local ethical committee. OF1 male mice were 2-6 months old (Charles River, France). Sperm from caudae epididymides were allowed to swim for 10 min at 37°C in 1 ml of M2 medium (Sigma-Aldrich, L'Isle d'Abeau, France). Sperm were then washed by centrifugation at 500g twice with M2 medium , and concentration adjusted for CASA analysis.
Sperm cryopreservation
Human sperm
Human semen was layered in a plastic tube of 50 ml, and mixed with Spermfreeze (Fertipro NV) (1/0.7 vol/vol) added drop by drop. The suspension was then mounted in straws and frozen first in liquid nitrogen vapor and then dipped in liquid nitrogen.
Bovine sperm
Fractions of ejaculate were diluted (1/1 vol/vol) at 34°C in OptiXcell medium (IMV Technologies, L'Aigle, France). After 10 min of incubation at 34°C, fractions were diluted to obtain a final concentration of 60 million of sperm/ml. Fractions were then cooled down to 4°C over 4 h then 0.2 ml straws were filled using an MRS1 device (IMV Technologies) and frozen using a DigitCool device (IMV Technologies) using the following parameters: from 4°C to −10°C at 5°C/min, from −10°C to −110°C at 40°C/min, from −110°C to −140°C at 20°C/min. Straws were then stored in liquid nitrogen. Straws were thawed for 30 s at 37°C before assessment in vitro.
Computer-assisted sperm analysis
Samples were divided in two equal samples in terms of volume: one was the treated sample and second was the control sample. For the treated sample, we added a certain volume of peptide (synthetic or natural) dissolved in ultrapure water, while in the control sample, we added the same volume of ultrapure water. Then, both samples were incubated for various times (from 10 min for standard tests to 240 min for analysis of long-lasting effects), and finally the different motility parameters were recorded. The time delay between testing the control and treated samples was around 1 min, and we shifted the order of samples between different experiments. After incubation, the sperm suspension was immediately placed into an analysis chamber (Leja Products B.V., Nieuw-Vennep, the Netherlands) of 100 μm depth for mouse sperm and 20 μm depth for human, NHP and bovine sperm, and kept at 37°C for microscopic quantitative study of sperm movement. Sperm motility parameters were measured at 37°C using a sperm analyzer (Hamilton Thorn Research, Beverley, MA, USA). The settings employed for analysis were as follows for human, NHP, bovine and mouse, respectively: acquisition rate: 60, 60, 60, 60 Hz; number of frames: 30, 20, 30, 45; minimum contrast: 80, 80, 80, 50 
Measurement of vitality of sperm treated with spermaurin
Forty microliter of sperm were mixed with 20 µl of eosin 1% diluted in NaCl 0.9% and 20 µl of nigrosin 10% diluted in NaCl 0.9%. Sperm were layered onto a glass slide and dried. A minimum of 100 spermatozoa were analyzed for each assay.
Venom separation and spermaurin isolation
Venom origin
Crude venom from S. m. palmatus was obtained from Alphabiotoxine Laboratory (Montroeul-au-Bois, Belgium) or Venomtech (Sandwich, Kent, UK). Ten milligram of lyophilized crude venom was dissolved in 500 µl of 100 mM ammonium acetate pH 6.8 and centrifuged at 10 000g for 10 min. Two hundred and fifty microliter of supernatant were used for further purifications.
Purification by size exclusion chromatography
Separation was performed on a Superdex peptide 10/300 GL gel filtration column (GE Healthcare, Uppsala, Sweden), with elution at 0.5 ml/min in 100 mM ammonium acetate pH 6.8. Fractions were collected every minute and the absorbance was monitored at 225 nm. The fractions were kept at −20°C until bioactivity screening and mass spectrometry analysis.
Purification of spermaurin from crude venom of S. m. palmatus
Prepurification by solid phase extraction
The crude lyophilized venom from S. m. palmatus (2 mg) was dissolved in 200 µl of 0.1% trifluoroacetic acid (0.1% TFA) and prepurified onto two serially linked SepPak C 18 Light columns (Waters Corporation, Milford, MA, USA), following the manufacturer's instructions and eluted with 3 ml 80% acetonitrile (ACN) in 0.1% TFA. The 80% eluted fraction was dried under vacuum using a vacuum system (Labconco, Freezone 2.5plus, Kansas City, MO, USA) and suspended in 0.1% TFA.
Analysis by online liquid chromatography coupled to electrospray ionization tandem mass spectrometry A fraction aliquot of an equivalent of 200 µg crude venom was injected for online electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) analysis on an Agilent HPLC HP-1290 system (Agilent Technologies, Santa Clara, CA, USA). Separation was performed on an Accucore C 18 column (2.1 mm × 150 mm from Thermo Scientific, Bremen, Germany), maintained at 35°C and online coupled to a Thermo Q-Exactive Orbitrap. Solvent A was 0.1% formic acid and solvent B was ACN in 0.1% formic acid. A linear gradient, starting from 4% B to 60% B for 120 min at a flow rate of 350 µl/min was applied to fractionate the venom components. The high-resolution mass spectrometer was operating in positive polarity and data-dependent mode. The Q-Exactive Orbitrap acquired a full-range scan from 380 to 2000 Th (70 000 resolution, AGC target 3.10 6 , maximum IT 200 ms) and then fragmented the top 10 peptide ions in each cycle (17 500 resolution, AGC target 10 5 , maximum IT 100 ms, intensity threshold 2 × 10 4 , excluding charge-unassigned ions, Normalized Collision Energy selected at 27). Parent ions were then excluded from MS/MS for the next 15 s. The software Chemstation B.04.03 (Agilent, Santa Clara, CA, USA) and Xcalibur™ 2.2 (Thermo Electron SAS, Courtaboeuf, France) were used to control the HPLC and the mass spectrometer, respectively.
Isolation of native spermaurin by reversed-phase HPLC
To isolate the bioactive fraction (called 7.8-purified fraction below), an equivalent of 1.7 mg of crude venom was injected using an Agilent HPLC HP-1290 system in the same conditions of elution as detailed above. Fractions were hand collected following the absorbance monitored at 225 nm, dried under vacuum and kept dried until use.
Matrix-assisted laser desorption/ionization mass spectrometry
For matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis, a Bruker Autoflex III equipped with the Smartbeam laser (Bruker Daltonics, Bremen, Germany) was used. Samples were diluted 1:10 in 0.1% TFA and deposited on the MALDI target using the sandwich sample preparation method with α-cyano-4-hydroxycinnamic acid (4CHCA) as matrix. Briefly, 0.5 µl of 4CHCA saturated in acetone was spotted onto a polished ground steel target (Bruker Daltonics), followed by the deposition of 0.6 µl of the acidified sampled and 0.4 µl of 4CHCA matrix prepared in 50% ACN in 0.1% TFA. Calibration was performed using a mixture of the Peptide Calibration II kit (mass range 700-4000 Da) and the Protein Calibration I kit (mass range 5000-17 500 Da). Acquisition was performed in a linear positive mode at a laser power setting over the ionization threshold using FlexControl™ 3.3 software (Bruker Daltonics). The data were processed under FlexAnalysis 3.2 (Bruker Daltonics) consisting on baseline subtraction, spectra smoothing and peak picking.
Peptide synthesis
Spermaurin was synthesized through native chemical ligation (NCL) of two peptide segments followed by oxidative folding to form the four disulfide bridges, using already described protocols. Briefly, an N-terminal cysteinyl peptide segment (sequence: were synthesized on a Prelude peptide synthesizer (Protein Technologies, Tucson, AZ, USA) using standard Fmoc/tBu chemistry at a 25 µmol scale starting from a Tentagel resin equipped with a Rink's amide linker, and including automated introduction of the N-2-hydroxy-5nitrobenzyl (Hnb) group trough on resin reductive amination. Both peptide segments were purified by C18 reverse phase (RP)-HPLC then chemoselectively coupled under standard NCL conditions (2 mM peptide segments, 50 mM tris-carboxyethylphosphine, 100 mM 4-mercaptophenylacetic acid, 6 M guanidinium chloride, 200 mM phosphate buffer, pH 6.5, 37°C, 18 h) (Lelievre et al., 2016; Terrier et al., 2016) . Purification by C18 RP-HPLC afforded the pure reduced form of spermaurin (sequence:
Peptide purification was performed by RP-HPLC on a Nucleosil C18 column (300 Å, 250 × 10 mm) (Macherey-Nagel, Düren, Germany), maintained at 25°C. Solvent A was 0.1% TFA in water and B was 0.1% TFA in ACN. A linear gradient, starting from 25% B to 45% B for 30 min at flow rate of 3 ml/min was applied and afforded the pure reduced form of spermaurin trough collection of the peak identified as the target compound. The purified compound was further analyzed by ESI-HRMS (Bruker maXisTM 22 ultra-high-resolution Q-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany), positive mode): [M+H]+ 23 m/z 7873.8160 (theoretical monoisotopic m/z calculated for C337H548N97O102S9:7873.8162) and analytical HPLC on a Chromolith HighResolution RP-18e column (150 Å, 10 × 4.6 mm) (VWR, Fontenay-sous-Bois, France), maintained at 25°C. Solvent A was 0.1% TFA in water and B was 0.1% TFA in ACN. A linear gradient, starting from 20% B to 50% B for 30 min at flow rate of 3 ml/min was applied. A single peak was observed at a retention time = 2.93 min under these conditions. Subsequent oxidative folding (10 µM peptide concentration, 0.1 mM oxidized glutathione, 1 mM glutathione, 1 mM EDTA, 100 mM TRIS, pH 8.5, 20°C, 24 h) (Da Silva et al., 2009; Derache et al., 2012 ) afforded a product that was purified to homogeneity by C18 RP-HPLC, and which MS analysis was consistent with the formation of four disulfide bridges. ESI-HRMS: Mouse IVF Two-cell embryos were produced as already described (Abi Nahed et al., 2014) . Briefly, eggs were collected from oviducts of synchronized OF1 females and sperm from cauda epididymis of OF1 males. Capacitated sperm were introduced into droplets containing oocytes in M16 medium (Sigma-Aldrich, France) and unbound sperm were washed away after 4 h incubation. Twenty-four hours after fertilization, 2-cell embryos (as an indication of successful fertilization) were scored. Number of replicates = 6.
Statistical analyses
The number of biological replicates is given as n and for each replicate, between 100 and 150 sperm were assessed per condition. Statistical analyses were performed with SigmaPlot 10.0 (Systat Software, Inc., San José, CA, USA). Student's t-tests were used to compare the effect of spermaurin on sperm motility versus control. Data represent mean ± SEM or SD, as indicated. Statistical tests with a two-tailed P-values ≤ 0.05 were considered significant.
Results
Presence of a compound which improves sperm motility in the venom of S. m. palmatus
The goal of this study was to discover original compounds able to improve sperm motility, inspired by our previous study showing that screening a library of compounds made from snake venoms enabled us to identify compounds able to modulate sperm motility (Escoffier et al., 2010) . In this study, we focused our attention on the venom of the scorpion S. m. palmatus. The crude venom was fractionated by SEC in 24 fractions (Fig. 1A) . A CASA system was used to test the effects of venom fractions on mouse sperm motility. We examined the following sperm motility parameters: VAP (µm/s), the straight-line velocity (VSL, µm/s), the curvilinear velocity (VCL, µm/s) and the amplitude of lateral head displacement (ALH, microns) (Fig. 1B) . One of the fractions, Fraction 8 (F8), stimulated the different parameters of sperm velocity. Although ART are used in the mouse species, improvement of sperm motility is not required, contrary to other species such as human and bovine. For this reason, the ability of F8 to improve sperm motility parameters was then tested on fresh ejaculated human and fresh epididymal bovine sperm. In human, there is a great variability among the different patients consulting at the department of reproduction, and for this reason, we plotted for each patient (n = 16) the percentage increase of VAP, VCL, VSL and ALH as a function of initial (non-treated) values (Fig. 2) . Figure 2 shows clearly that F8 improved the four sperm motility parameters and that the potency of the fraction was inversely proportional to the initial value of the parameters measured without treatment. Contrary to human sperm, bovine sperm present a noticeable homogeneity among the different bulls, and most of them presented a high percentage of motile sperm (70-75%, n = 6, fresh epidydimal bovine sperm). As observed for human sperm with the highest motility parameters, F8 poorly stimulated high performing bulls' sperm (Fig. 3) . Nevertheless, we found one bull with poorer parameters, with a VCL < 155 µm/s, and interestingly F8 improved the VCL of this bull's sperm (Fig. 3) . These experiments clearly showed that F8 contained one or several compounds able to improve motility of fresh sperm in mouse, bovine and human, the two latter species being particularly relevant in the framework of ART improvement.
Identification of a peptide of 73 amino acids responsible for the effect on sperm motility
The next step was to identify the chemical nature of the compound(s) responsible of the biological effect. Several types of molecules are present in venoms, including proteins, peptides and polyamines. In order to test the hypothesis that the chemical nature of the molecule(s) responsible for the observed biological effect was a protein or a peptide, F8 was incubated with proteinase K at 56°C for 1 h before testing its activity on sperm motility (Fig. 4) . This protease was chosen because of its weak specificity and its action on a broad type of protein or peptide substrates. We first checked that proteinase K (100 µg/ml) heated at 56°C had no effect by itself. The increase of sperm motility observed in the presence of F8 was blocked when the fraction was pretreated with proteinase K (Fig. 4) . This result strongly suggested the protein or peptide nature of the molecule(s) responsible for the biological effects. Moreover, we previously calibrated the gel filtration column with protein standards (cytochrome C, aprotinin and vitamin B12) (Escoffier et al., 2010) and showed that F8 co-eluted within the mass range of 5-12 kDa. Altogether, these results indicated that the active compound in F8 was likely a polypeptide/small protein. In order to go further in the identification of the bioactive compounds present in F8, MALDI-MS analysis was performed on the active F8 and on the two surrounding fractions (F7 and F9) in order to determine the complexity and the molecular mass of the compounds present in these fractions (Fig. 5 ). In F8, four different molecular ions were observed at m/z 3946, 4270, 7860 and 8552 (average values, see Fig. 5, F8 ). In fraction F7, which had no effect on sperm motility, only a molecular ion at m/z 4249 was detected. In contrast in F9, which had a very small positive effect on sperm motility, several molecular ions were detected at m/z ranging from 3670 to 12 043 f. The comparison of the different mass spectra obtained on F7-F9 allowed the identification of a unique peptide present in F8 and F9 at m/z 7860.3 and 7861.2, respectively (see Fig. 5, F8, F9 ). To confirm that the 7.8 kDa molecule was responsible for the biological effect, we next purified this peptide by online LC-ESI-MS/MS in a two-step approach. After prepurification of the crude venom (~2 mg) by solid phase extraction, a fraction aliquot (equivalent to 200 µg of crude venom) was subjected to reversed-phase chromatography by online LC-ESI-MS/MS to determine the retention time of the 7.8 kDa molecule, which was 40.67 min as observed in 
Figure 4 Treatment of fraction 8 (F8) by proteinase K inhibits its
biological activity on sperm motility. Washed ejaculated human sperm (n = 3 replicates) was either incubated with F8 (dilution 1/20, as obtained above), or with F8 pretreated with proteinase K (Prot K) at 56°C for 60 min. Heated proteinase K added at the same concentration had no effect on sperm motility. Heat by itself has no effect on biological activity of F8. For each replicate, between 100 and 150 sperm were assessed per condition. Data represent mean ± SD. Statistical differences were assessed using t-test. *P < 0.05 versus control.
(Panel A2). To go further into the isolation and characterization of the 7.8 kDa peptide, an equivalent of 1.7 mg of crude venom was injected on the same column without coupling the LC to the mass spectrometer to collect manually three fractions eluting between 38 and 41 min (Fig. 6B) , following the absorbance at 225 nm. The presence of the 7.8 kDa was confirmed by MALDI-MS (data not shown) only in the fraction eluted between 39 and 40 min. The potency of the three collected fractions was tested on the motility parameters of human sperm and only the fraction comprising the 7.8 kDa peptide improved the four sperm motility parameters (Fig. 7) . This fraction was called 7.8-purified fraction. Similar to what observed with the SEC fraction, the potency of the purified 7.8 kDa peptide was inversely proportional to the initial value of the parameters measured without treatment (Fig. 7) . These results strongly suggest that 7.8 kDa peptide is responsible for the improvement of the sperm motility parameters. Interestingly, the transcriptome of the venom gland of S. m. palmatus was recently released (Abdel-Rahman et al., 2013) , and there is only one peptide with a molecular mass at 7.8 kDa, referred to as Smp73. This peptide, belonging to the family of the La1-like peptide, has 73 amino acids, including eight cysteines presumably involved in four internal disulfide bonds and a putative amidated C-terminus, with the following deduced amino acid sequence: SGESCKAGKFTVLVGHQQNDKSTCTLYKCLNFKRKYALQISSCAD VDLKSGCRQVPGAASANFPECCPMVICK-NH2 . These results strongly suggest that the 7.8 kDa peptide purified in our experiments corresponds to the Smp73 peptide identified by transcriptomics in Abdel-Rahman publication.
To confirm the identity of the 7.8 kDa present in 7.8-purified fraction as Smp73, we first synthesized Smp73 through NCL of two segments, making use of our recently described methodology for the Fmoc-based solid phase synthesis of the thioester segment (Mende and Seitz, 2011) , based on a stable 'crypto-thioester' precursor that is converted in situ into a reactive thioester . Subsequent oxidative folding using a glutathione-based redox buffer (Da Silva et al., 2009; Derache et al., 2012 ) afforded a peptide with a 8-Da decrease in mass (Fig. 8A) , consistent with the formation of four disulfide bonds (Nagao et al., 2015) . This synthetic peptide showed an identical retention time in RP-HPLC and molecular mass as the natural product, suggesting a native fold (data not shown). Next, a new fractionation of the scorpion S. m. palmatus crude venom was performed and the peptide of 7.8 kDa was found by MALDI-TOF-MS (TOF, time of flight) to be present in the fraction #40, eluted at the retention time between 39 and 40 min. Fraction#40 and the synthetic peptide Smp73 were then analyzed by LC-MS/MS before and after reduction-alkylation to assist in the identification of spermaurin as Smp73. Two compounds sharing the same mass and the same multicharge profile were found at the same retention time, before and after reduction-alkylation (data not shown). This confirms that both peptides have the same number of cysteines and are C-terminally amidated. In the reduced-alkylated samples, an oxidized form of this peptide was also found and is the major form for the crude venom fraction #40. Additionally, the sequence of the peptide from the crude venom fraction was partially determined from one MS/MS spectrum (Fig. 8B) . The ion at m/z 477.229 2+ corresponded to the peptide's N-terminal fragment SGESCKAGK, including an alkylated cysteine. An estimated amount of~5 µg/mg of crude venom of this peptide was determined to be present in 3.4 mg of crude venom, thanks to the data obtained by LC-ESI-MS/MS and to the availability of the synthetic peptide. We finally tested the biological effect of the synthetic peptide on sperm motility to unequivocally demonstrate that the 7.8 kDa peptide corresponds to Smp73. We first determined the dose-response curve of the synthetic peptide on frozen-thawed human sperm and its activity corresponded to a bell-shape curve and the maximum activation was obtained at concentrations around 170 nM (Fig. 9 ). Activity was next tested on frozen-thawed bovine and human sperm from fertile donors (Fig. 10A, B ) and fresh epidydimal mouse sperm (Fig. 10C) at the potent concentration of 170 nM. The results clearly showed that the synthetic peptide was able to improve sperm motility as the natural 7.8 kDa did. Altogether, these results demonstrated that the 7.8 kDa found in F8 and purified by LC/MS corresponds to the La1-like peptide of 73 amino acids identified by transcriptomic analysis and called initially Smp73. As the peptide was extracted from S. m. palmatus scorpion and because of its activity on sperm, we called this peptide 'spermaurin'.
Spermaurin does not affect sperm viability and has a long-lasting effect on sperm motility
Although none of the La1-like peptides tested so far showed any cellular or in vivo toxicity (Quintero-Hernandez et al., 2015) , the viability of the sperm incubated with spermaurin was assessed. Human fresh ejaculated sperm were incubated for up to 240 min with the peptide and the percentages of viable sperm were measured by eosin-nigrosin staining and compared to the percentage of untreated viable sperm (Fig. 11A) . No difference was observed between the two conditions, confirming the absence of toxicity of spermaurin. In vitro, the motility of sperm decreases rapidly and we wondered whether the stimulation of sperm motility by spermaurin could affect the kinetics of sperm motility decrease. To answer this question, VCL of ejaculated human sperm was followed for 240 min in the presence or absence of spermaurin. The VCL of treated sperm was always higher than control VCL during the whole 240 min, indicating that spermaurin prevented the motility decrease over time (Fig. 11B ).
Spermaurin is a potent tool to improve testicular sperm motility
We clearly showed above that spermaurin improved key parameters of fresh epididymal and ejaculated sperm motility. The next step was to assess if spermaurin can improve testicular sperm motility. In human, testicular sperm is collected for use in ART in patients presenting either obstructive or non-obstructive azoospermia. However, testicular sperm have a very low motility and remain embedded in the testicular tissue. To circumvent this problem, compounds able to increase their motility are often used, thus helping sperm collection and recovery of the most mature sperm. At this stage, testicular Figure 7 The 7.8-peptide purified by HPLC/MS has similar activity to F8 on sperm motility parameters. Washed ejaculated human sperm aliquots (n = 20 replicates) were treated with 1/40 of 7.8-purified fraction (fraction 34) for 10 min and sperm motility parameters (VCL, VSL, VAP and ALH) were measured. Data are expressed as percentage of increase of the initial motility parameters measured on the corresponding non-treated sperm aliquot. Data were fitted with the equation: variation = ae −bx + ce human sperm recovery to test spermaurin was not possible. We therefore tested spermaurin on testicular NHP sperm. Macaca testicular sperm was collected from Cynomolgus monkeys (M. fascicularis) euthanized for other research purposes. Testicular NHP sperm were incubated for 10 min either with the natural or the synthetic spermaurin. Sperm motility parameters were measured with the CASA system before and after treatment (Fig. 12A) . The comparison of the dot plots clearly shows that spermaurin increased sperm motility parameters, increasing both the number of motile sperm and the mean VCL (Fig. 12BC) .
Spermaurin increases fertilization outcome in mouse
The percentage of motile sperm directly influences the rate of IVF (Publicover and Barratt, 2011) and because spermaurin increased both the percentage of motile sperm and the mean VCL, the ability of spermaurin to increase the yield of IVF in mouse was assessed. This work was carried out before we obtained the synthetic spermaurin and was therefore carried out using the 7.8-purified fraction diluted at 1/40, a dilution known to improve sperm motility parameters. Spermaurin was introduced into the droplets containing the pooled eggs from several synchronized females at the same time as the sperm and IVF was evaluated as the percentage of 2-cell embryos (ratio of the number of 2-cell embryos to the number of layered oocytes within one droplet), 24 h later (Fig. 13 ). Gamete treatment with spermaurin increased the yield of 2-cell embryos after IVF from 47.2 ± 1.5% to 58.6 ± 3.8% (n = 6, P < 0.001), representing an increase of 24%, and thus suggests that increasing sperm motility parameters with spermaurin improves IVF outcome in mice.
Discussion
Spermaurin as a new tool for sperm motility enhancement
Herein, we showed that a DRP of the venom of S. m. palmatus, and called herein spermaurin, is a potent compound able to significantly improve different sperm motility parameters in several mammalian species and improves IVF outcome in experiments in mouse. Spermaurin is effective on fresh testicular, epidydimal and ejaculated sperm. It also improves frozen-thawed ejaculated sperm motility in human and bovine species. This compound represents a promising tool for use in ART. Spermaurin could thus be considered as a new lead compound to enhance sperm motility and the present work paves the way for the development of new peptides or peptidomimeticbased drugs with simpler structures and more potent activities.
This work confirms the great interest in venom DRPs for 'biologics' development. Indeed, venoms have been successfully used for the development of marketed painkillers, and metabolic disease and cardio-vascular drugs (Harvey, 2014) . For example, Prialt ® (25 aa, six Cys), isolated from the venom of the cone snail Conus magus, selectively blocks N-type voltage-gated calcium channels and is the only approved non-opioid therapy for severe chronic pain (Miljanich, 2004) . A peptide from viper venom, Integrilin ® is used in the treatment and prevention of acute coronary syndrome. More than 20 other venom-derived reticulated peptides are under development by pharmaceutical companies, illustrating the major interest in the venoms as a source of DRPs for drug discovery, a rapidly emerging scientific research area. Spermaurin would expand the use of venom DRPs to the field of assisted reproduction for the first time. Although assisted reproduction already benefits from 'biologics', such as gonadotrophins for ovarian stimulation, spermaurin is the first 'biologics' proposed for sperm enhancement. The potential use of spermaurin or its derivatives in ART should be facilitated for the following reasons: first, spermaurin would be added directly into the sperm incubation medium and the peptide could thus directly reach its target, avoiding any difficulty of biodistribution; second, the presence of disulfide bonds greatly improve its stability and the peptide could be mixed in a defined protease-free medium, avoiding lack of activity over time; third, the immunogenicity of DRPs, being small and stable miniproteins, is generally considered to be absent or weak, and last but not least, spermaurin belongs to the La1-like peptide family, a family known for its absence of toxicity (Quintero-Hernandez et al., 2015) . Because spermaurin is a large peptide of 73 amino acids, and is unlikely to cross the plasma membrane freely, it likely activates a noncharacterized pathway to increase sperm motility. Its action site is most probably a membrane receptor or an ion channel, contrary to already characterized compounds known to stimulated sperm motility such as pentoxifylline or LY294002. Previous compounds act indeed mainly on the kinase pathway ending with PKA or by inhibiting sperm phosphodiesterases, in order to increase cyclic-AMP concentration within the cell (Tardif et al., 2014) . It will be important to characterize the receptor for spermaurin in order to identify the molecular pathway activated by the peptide as this putative receptor could constitute a new target for developing other treatments to improve sperm motility or to block motility as a new lead for male contraception.
Differences in potency of different venom samples/preparations
The graphs obtained with the F8 fraction (Fig. 2) and the 7.8-purified fraction (Fig. 7) , although similar, present specific features. First, they present different levels of maximum VCL enhancement: with F8, the VCL of samples presenting the lowest motility values was increased by 35% whereas with the 7.8-purified fraction, the VCL of samples presenting the lowest motility values was increased by 90%. Second, F8 decreased the VCL of samples presenting the highest values (>80 µm/s) by 5%, whereas the 7.8-purified fraction did not modify the VCL of these samples. Third, the relation between the percentage increase and the initial value of VCL is no longer linear but exponential. Several reasons likely explain these differences. First, the expected concentration of spermaurin should be higher in the F8 fraction (dilution 1/20 of 12.5 mg) than in the 7.8-purified fraction (dilution 1/40 of 1.7 mg). We have shown that the potency of spermaurin is maximum around 200 nM and decreases at concentrations higher than 500 nM (Fig. 9) and the lower effect of the F8 fraction may thus be due to a higher concentration of spermaurin in this fraction; It is worth noting that there is an uncertainty in the comparison of the concentrations of spermaurin in both fractions because the purifications were carried out using venoms from different suppliers and it is well known that the proportion of the different components of a specific venom may differ from batch to batch. Second, the F8 fraction contained several compounds as clearly shown by MS analyses (Fig. 5) and the difference observed between both fractions may also be due to the presence of inhibitory/toxic compounds in F8.
First biological effect for a La1-like toxin
Venoms from scorpions contain different well-characterized families of peptides. Most of them are neurotoxic peptides that target ion Figure 10 The synthetic peptide obtained by native chemical ligation (NCL) enhances sperm motility parameters. (A1-3) Effect of synthetic spermaurin (270 µg/ml stock solution; dilution at 1/200 corresponding to a concentration of 170 nM) on human frozen-thawed sperm samples (n = 12 replicates) on mean VCL (mean ± SD) (A1), on VCL of each sample (A2) (data are expressed as the percentage of increase of the initial VCL measured on the corresponding non-treated sperm aliquot) and on the percentage of total motile sperm cells (VAP > 1 µm/s) (A3). (B1-3) Similar experiments and results for bovine frozen sperm samples (n = 9 replicates). (C1-3) Similar experiments and results for fresh mouse epidydimal sperm samples (n = 6 replicates). For each replicate, between 100 and 150 sperm were assessed per condition. Statistical differences were assessed using paired Student's t-test. *P-value as indicated versus control. channels and paralyze their prey. Nevertheless, there are also other families of peptide, such as antimicrobial peptides and peptides with unknown functions. Among these peptides with unknown function, there is a family of DRPs, named the La1-like family, which was first isolated from the venom of the scorpion Liocheles australasiae (Liochelidae family) and originally called La1 peptide (Miyashita et al., 2007) . La1 was presented as the most abundant component of the venom of L. australiase and this suggests that this peptide may have an important biological function. Moreover, these peptides are found in many toxic and non-toxic families of scorpions. La1-like peptides were found in different species belonging to the Scorpionidae family, such as Opisthacanthus cayaporum , Pandinus cavimanus (Diego-Garcia et al., 2012) and S. m. palmatus (Abdel-Rahman et al., 2013) , the Euscorpiidae family such as Scorpiops margerisonae (Ma et al., 2012) , the Urodacidae family such as Urodacus yashenkoi (Luna-Ramirez et al., 2013) , the Buthidae family such as Lychas mucronatus and Isometrus maculatus (Ma et al., 2012) and the Vaejovidae family of Vaejovis spp. (Quintero-Hernandez et al., 2015) . These peptides are thus found in 6 of 17 families of scorpions so far. Interestingly, it is worth noting that peptides homologous to La1 were also found in ticks and insects (Sheldon et al., 2007; Ribeiro et al., 2011) , confirming that they may have an important biological function. However, the function of this family of peptides remains unknown so far. Herein, we have shown for the first time that the La1-like toxin of S. m. palmatus is able to modify sperm motility and this result strongly suggests the presence of a specific receptor for this peptide on the sperm plasma membrane. The characterization of this receptor will likely provide clues to identify the molecular targets of this family of scorpion peptides and may allow characterization of their biological function.
In conclusion, since 2007, we have screened natural compound libraries for substances controlling sperm motility (Escoffier et al., 2010 (Escoffier et al., , 2011 and this report presents spermaurin, a unique peptide that significantly improves sperm motility and fertilization. It is worth noting that spermaurin improves the motility of both fresh and frozen-thawed Figure 11 Spermaurin does not modify human sperm viability and has a long-lasting effect. (A) Viabilities of ejaculated human sperm, assessed by a eosin-nigrosin test, continuously exposed to purified spermaurin (7.8-purified peptide prepared as indicated above) for up to 240 min (○) and control sperm (•) were measured at various times (n = 4 replicates). Values are expressed as percentage of viability at t = 0 min. (B) VCLs of ejaculated human sperm continuously exposed to purified spermaurin for up to 240 min (○) and control sperm (•) were measured at various times (n = 4 replicates). For each replicate, between 100 and 150 sperm were assessed per condition. All data are mean ± SEM. sperm collected in epididymis, testis or ejaculate. Moreover, it is active on sperm from different mammalian species, suggesting that it targets a major and conserved pathway controlling sperm motility. However, spermaurin is a complex peptide of 73 amino acids containing 4 disulfide bridges and likely represents in the process of drug discovery a lead compound. Similar to what was done with 'Bradykinin Potentiating Factor', a peptide from the venom of Bothrops jararaca, which allowed the design of Captopril ® , a powerful antihypertensive drug, further studies need to be performed to drive spermaurin and its analogs toward use as a medical compound. These studies should include the identification of the molecular pathways activated by spermaurin, the characterization of its 3D structure and the synthesis of lower molecular weight analogs with improved potency. Figure 12 Purified spermaurin stimulates fresh non-human primate testicular sperm. (A) Vertical point plots of VCL values for control and spermaurin (7.8-purified fraction, dilution 1/40) treated testicular sperm (n = 3 replicates). Sperm treated with spermaurin have a higher VCL than control (P < 0.001). (B) Mean ± SEM percentage of motile (VAP > 1) and progressive (VAP > 25 and Straightness > 80%) for control and spermaurin treated testicular sperm (n = 3 samples). (C) Mean values ± SEM for the four main parameters. For each replicate, >50 sperm were assessed per condition. Statistical differences were assessed using paired Student's t-test. *P-value as indicated versus control.
Figure 13
Purified spermaurin increases IVF outcome in mouse.
Sperm and oocytes were mixed and incubated in M16 medium with or without purified spermaurin (for 4 h; dilution 1/40). Mean values ± SD of the percentages of 2-cell embryos were measured 24 h later. The value n represents the number of males tested and for each male between 12 and 33, oocytes were fertilized in each group. Percentages of 2-cell embryos were calculated for each male and correspond to the ratio of the number of 2-cell embryos to the number of collected oocytes. Statistical differences were assessed using paired Student's t-test. *P < 0.001 versus control.
